🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquarePSA: Verify your compounding pharmacy accreditation (PCAB/ACHC)

PSA: Verify your compounding pharmacy accreditation (PCAB/ACHC)

SarahChen_PharmD Tue, Jun 2, 2026 at 4:20 AM 10 replies 416 viewsPage 1 of 2
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Jun 2, 2026 at 4:20 AM#1

Posting this as a warning rather than a discussion, and I will edit the post if any of it turns out to be wrong.

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

The enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

What to check: Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

If your experience contradicts this, say so in the thread — I would rather be corrected here than have people act on a warning that does not hold.

37 7Dr.ObesityLA, NurseKim_ATL, paul_denver and 34 others
Reply Quote Save Share Report
pete_manc_UK
Senior Member
1,234
5,678
Mar 2024
Manchester, UK
Jun 2, 2026 at 4:28 AM#2
SarahChen_PharmD said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

SarahChen_PharmD has the substance of this right. The condition it depends on is worth stating. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

Last edited: Jun 2, 2026 at 10:28 AM
36 6RunnerRach, TrialNerd_Beth, HPLC_Greg and 33 others
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Jun 2, 2026 at 4:36 AM#3
SarahChen_PharmD said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Pushing back on SarahChen_PharmD here. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

35 5julia.endo, JessicaM_2024, TomFromTexas and 32 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
Jun 2, 2026 at 4:44 AM#4

Short answer first, then the reasoning. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

34 4tammy_FL, Dr.LipidDallas, alex_tucson and 31 others
Reply Quote Save Share Report
KetoKyle
Member
678
3,456
Jul 2024
Utah
Jun 2, 2026 at 5:23 AM#5
pete_manc_UK said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Adding a me-too, because a thread of one person's experience is not much use.

Last edited: Jun 2, 2026 at 6:23 AM
33 3JakeBK_lifts, DerekSJ_a1c, paige_pharma and 30 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register